In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS

From optimal medical therapy to revascularisation.

Session New 2013 ESC Guidelines on stable coronary artery disease

Speaker Bernard Gersh

Event : ESC Congress 2013

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Symposium

This content is currently on FREE ACCESS

Two columns page  

New 2013 ESC Guidelines on stable coronary artery disease

Chronic Ischaemic Heart Disease (IHD)

 

One important new aspect of these guidelines is that functional coronary disease plays a much larger role than in the previous version of the guidelines from 2006. Filippo Crea outlined that microvascular disease was a prevalent cause of angina. The diagnosis is made by demonstrating the reduced flow reserve associated with the disease, for instance by PET or external Doppler of the left anterior descending artery after adenosine challenge. Treatment starts with betablockers and may – in case these do not provide sufficient relief – be supplemented by calcium antagonists of the dipyridine type. A new drug with promise for this condition is ranolazine.
Coronary vasospasm is another functional disease of the coronaries causing angina. If spasm is focal, ST-elevation may ensue with potentially deleterious consequences. Thus, high dose calcium antagonist treatment is important. In refractory cases this may potentially be supplemented by focal stenting at the site of spasm. Details can be found on the web, where the guidelines can be viewed

Stephan Achenbach explained the basic philosophy of the guidelines. There are three steps in this disease. First, the pre-test probability needs to be determined based on the type of symptoms and the age and sex of the patient. Second, the optimal test is selected for the particular patient, based on patient profile, and local availability and expertise with the techniques. Third, the risk of events is stratified and a decision on how to proceed is made based on this information. If angina is very severe, all steps can be bypassed and invasive coronary angiography can be performed without priori non-invasive testing, but it may need to be complemented by determination of fractional flow reserve (FFR). The role coronary CT angiography is to exclude significant disease in those patients who have pretest probabilities in the low - intermediate range, and are suitable candidates for a CT scan.

Jean-Sebastien Hulot described the optimal medical treatment of patients focussing on antianginal drugs and drugs that improve prognosis. Whereas the first line antianginal drugs have not changed since the last guidelines, new second line drugs such as ivabradine and ranolazine have become available and should be used if first line drugs fail.

Finally, Bernard Gersh summarised the recommendations on revascularisation. This intervention should be reserved for patients in whom evidence is strong that prognosis can be improved. Typical constellations are patients with large areas of ischemia corresponding to left main stenosis and multivessel disease, including the proximal left anterior descending. Especially for complex coronary anatomy, in patients with a low surgical risk, bypass surgery is the method of choice for revascularisation.

References


749

SessionTitle:

New 2013 ESC Guidelines on stable coronary artery disease

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

 

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are